Alan K. Hauser

Alan K. Hauser Email and Phone Number

Chief Executive Officer @ Health Discovery Corp.
United States
Alan K. Hauser's Location
United States, United States
Alan K. Hauser's Contact Details
About Alan K. Hauser

As a bioscience business executive, I champion accelerated growth & shareholder wealth by translating the promise of proprietary multiomic testing tools & product pipelines into practice for patient benefit, e.g., ◘ AI/ML-enabled data analytic solutions for biopharma drug development & diagnostics using microfluidic, microarray, tissue/organoid imaging, phage-display/NGS & liquid-biopsy platforms◘ small molecules (neurodegenerative/CNS disease), bi-specific antibody immunotherapy, peptide/Ab targeted radiotherapy (oncology), regenerative stem cells (wound care).My precision-medicine innovation-to-commercialization (I2C) efforts aim to improve people’s lives & have contributed to:► completed 65 Biz Dev alliances + 3 acquisitions valued at $320 M► built biotech businesses resulting in 5 M&As (>$1.8 B) + 2 IPOs ($26 M & $189 M) ► led a multidisciplinary team with $150 M of intellectual property (IP)-based pharmaceutical compound licensing revenue/year► directed commercial development for eventual Nobel-prize winning homologous DNA recombination to enable tumor-cell immunity methods & gene therapy► launched 9 products for genomics-guided drug discovery & in-vitro diagnostics► gave >40 presentations on commercializing converging bio-nano-informatic technologies & CDx-precision cancer care in Asia, Europe & North America.Drawing from my cross-functional capabilities for managing moving organizational pieces (programs, personnel, processes & projects), I advance disruptive biomed breakthroughs from idea to implementation with optimal outcomes by operationalizing I2C vision & global BizDev goals.To cross the chasm from healthcare innovation to commercialization, a potential valley of death, I apply my☞ leadership success in strategic planning, promoting, prospecting, appraising + partnering☞ interpersonal skills to nurture relationships & navigate stakeholders by influencing with persuasion. Known as a ’tri-lingual’ (biotech, business, patent law) bridge-building executive & Certified Licensing Professional (CLP), I'm enthusiastic about boosting pioneering discoveries & inventions from the bench to marketplace via return-on-investment led collaborations that traverse the I2C divide.Bio-Innovation-to-Commercialization (I2C) Specialties♦ Opportunity Scouting, Due Diligence ♦ Tech-IP-Product-Market Fit/Decision Analysis♦ Team Leadership, Talent Development & Mentoring ♦ Go-to-Market Launch, FTO, Roadmapping + Resource Allocation♦ ROI Valuation, License/Contracts Negotiation & Project/Alliance Management

Alan K. Hauser's Current Company Details
Health Discovery Corp.

Health Discovery Corp.

View
Chief Executive Officer
United States
Website:
healthdiscoverycorporation.com
Employees:
1
Alan K. Hauser Work Experience Details
  • Health Discovery Corp.
    Chief Executive Officer
    Health Discovery Corp.
    United States
    View
  • Health Discovery Corporation
    Chief Executive Officer
    Health Discovery Corporation Jul 2024 - Present
    Health Discovery Corporation (HDC) has been at the forefront of Support Vector Machine (SVM) development, pioneering groundbreaking pattern-recognition methodologies and securing seminal patents to safeguard its innovative technologies within the burgeoning machine learning field since 1998. Today, HDC’s contributions are far-reaching, as SVM classifiers have become indispensable tools utilized across diverse industries.Mission: HDC is creating growth opportunities for our collaborators in disparate markets to gain access to the Company’s broadly enabling SVM technology. Doing so means our business partners can deploy the necessary proprietary SVM methods for supporting their specific data analytics applications. Through strategic value-added alliances, we aim to empower organizations in numerous sectors with advanced SVM solutions, including Recursive Feature Elimination (RFE), accelerating progress in precision medicine and beyond.
  • Leaders In Life Science Licensing & Biotech Business Development
    Bio-Innovation-To-Commercialization Mentor & Coach
    Leaders In Life Science Licensing & Biotech Business Development 2011 - Present
    As a Certified Licensing Professional (CLP), I founded the educational council “Leaders in Life Science Licensing & Biotech Business Development” with a goal of disseminating & advancing strategic business development (SBD) & licensing information & understanding among the extended network of CLP leaders, Licensing Executives Society (LES) colleagues as well as neophytes & students. The council is committed to promoting & encouraging intrapreneurial collaborative interaction & sharing among group members pertaining to:Emerging omics & biotechnology Innovation to Commercialization (omics•I2C), new venture creation, funding & financial valuations (schematics below highlight SBD experience & specific Bio•I2C projects);Lean bio-business building & product roadmapping (additional strategic planning info is in the Work-Experience & Projects sections);Value-added contribution of multiomics-guided companion diagnostics (CDx) testing tools in the CDx-stratified-medicine ecosystem.Related omics tools • I2C information is provided at my personal website.
    View
  • Omics Innovation To Commercialization
    International Speaker & Industry Expert On Biotech Business & Strategy Development
    Omics Innovation To Commercialization Aug 2004 - Present
    Palo Alto, California, Us
    I have presented more than 40 Innovation-to-Commercial (I2C) talks, including invited presentations at international conferences as well as across the U.S. Representative topics are:Commercializing Companion Diagnostics-Stratified Medicines: Competing Economic & Ethical ConsiderationsOct 1, 2013 at Mayo Clinic's Individualizing Medicine Conference in Rochester, MNEthical Ramifications of Companion Diagnostics-Stratified HealthcareJun 8, 2013 at the American Chemical Society (ACS) regional meeting in La Crosse, WIEstablishing the financial impact of biomarker-based genetic testing within the companion diagnostics (CDx)-stratified medicine ecosystemDec 4, 2012 at the Molecular Medicine & Diagnostics World Congress in Guangzhou, ChinaConverging Bio-Nano-Info-Tech Innovation to Commercialization (I2C) IssuesOct. 24, 2004 at the IFBT, Beijing, ChinaConverging bio-nano-info-technology licensing considerations: the determination of fair & reasonable royalty rates for genetic content (biomarkers) as part of an integrated sample-to-solution molecular DNA diagnostics platform & IVD panelsFeb 12, 2004 at the Licensing Executive Society meeting in San FranciscoBusiness Development Issues relating to Converging Bio-Nano-Info-Tech Innovation to Commercialization (I2C) Jan. 15, 2004 at the NIBC, IsraelCommercializing convergent bio-nano-info-technologiesOct 15, 2003 at the GATIC Conference, Tokyo, JapanConverging Bio-Nano-Info-Tech Innovation to Commercialization (I2C)Sept. 22, 2003 at the National Science Foundation (NSF), Arlington, VAAt Northwestern University (NU):NU I2C classes at the McCormick School of Engineering, Evanston, IL – 2008 to 2013NU I2C classes & seminars at the Feinberg School of Medicine, Chicago, IL – 2008 to 2011NU I2C boot camps, workshops, student group seminars, Evanston & Chicago, IL – 2008 to 2011Contact me at akhauser@me.com for details.
    View
  • Arvetas Biosciences
    Chief Executive Officer
    Arvetas Biosciences Sep 2020 - Jun 2024
    Spatial biology company developing multiomic translational drug-discovery and companion diagnostic tools to enable precision medicine.Having charted and executed the Arvetas Innovation-to-Commercialization (I2C) roadmap, I've completed the following:• Created business model; built pro forma P&L forecast & pitch deck yielding startup capital• Co-authored successful National Cancer Institute proposal & resulting SBIR funding was deployed: – To hire & lead a multidisciplinary team that developed & demonstrated proof-of-principal operation of the machine learning-powered multiomic spatial profiling (MSP) platform for precision oncology• Drove competitive technology-intellectual property-new-product landscaping & IP licensing – Established preliminary freedom to operate & secured exclusive world-wide rights to required IP• Spearheaded technology-product-market fit through customer discovery & market researchArvetas is developing an ML-enabled multiomic spatial profiling (MSP) platform, which unlike other spatialomic technologies, can directly interrogate a large number of biomarkers in clinical tissue with only one round of direct staining and imaging. By simultaneously collecting transcriptomic and proteomic expression signatures while preserving the contextual relationships among cellular neighborhoods within the tumor-immune micro-environment, this molecular mapping system is currently helping the R&D community elucidate an added dimension of spatial understanding and quantification of the native tumor architecture. The proprietary ML-driven MSP solution not only scales for molecular-marker/drug-discovery and translational research applications, including tumor atlas construction, but the same Arvetas platform is uniquely positioned to have valuable clinical utility as a companion diagnostic tool for enabling stratified precision cancer care.
    View
  • Cdx Precision Health
    Business Development Svp & Stratified Medicine Practice Leader
    Cdx Precision Health Jul 2011 - Sep 2020
    Palo Alto, Ca, Us
    By characterizing the pharmaco-economics of precision healthcare using biomarker-enabled companion diagnostics (CDx) as Real Options within a decision-tree analysis framework, we’ve determined the financial value added by the CDx molecular test within the stratified medicine system. More information regarding the consultancy's capabilities catalyzing precision care•I2C can be found at the firm's website, www.CDxPrecisionHealth.com. ►► For the representative oncological cases investigated, the risk-adjusted expected Net Present Value (eNPV) of the financial model predictions is in excess of $250 Million. ◄◄The results of these economic studies are being used to help level the playing field among key stakeholders, including diagnostic biotool testing & targeted treatment healthcare-providers + payers.On behalf of CDx Precision Health, I was also invited & spoke at a Molecular Medicine & Diagnostics Conference in China ('12), presented at an American Chemical Society (ACS) meeting ('13) & at the Mayo Clinic's Individualizing Medicine Conference ('13) as well as led an in vitro Dx (IVD) panel discussion at the BIOMEDevice San Jose 2018 conference. Having assessed the CDx/t•Rx landscape, its market size & growth forecasts, I'm optimistic about the genomics-guided precision care field encompassing targeted therapies for oncological immune disorders + other disease indications.Previously: Strategic Commercial Development SVP & Companion Diagnostics-Stratified Medicine Practice Leader
    View
  • Northwestern University
    Business Development Executive Director/Director | Tech Commercialization | Ip Licensing | Marketing
    Northwestern University Feb 2008 - Jun 2011
    Evanston, Il, Us
    » As Technology Licensing & Business Development Executive Director of Northwestern's Innovation & New Ventures Office, starting in Feb. 2010, when promoted from BD Dir, through to June 2011,Directed NU's tech licensing group of 5 full-time scientific/engineering staff, each with an advanced graduate degree, plus > 30 entrepreneurs in residence (EIR interns) that conducted the following: ● Tech transfer team evaluated approximately 200 invention disclosures per year & commercially assessed > 50 I2C opps in partnership with the executive & student/postdoc EIR interns;● Executed 30 new license agreements, with 20 pending, in academic year 2010-2011 & more than 20 transactions/opportunities were directed toward diagnostics (Dx) testing tools for IVD companies or therapeutics (Rx) for pharmaceutical & biopharma corporations;● Managed, marketed & licensed proprietary portfolios of Rx candidates + Dx content & biotools to treat + test for various disease indications, including cancers, blood-related disorders & immune deficiencies.» As Business Development Director of NU's Technology Transfer Program from Feb. 2008 to Feb. 2010,Bridged the gap between NU research & its practical use for public benefit resulting in the following:● Marketed more than 150 NU embryonic/emerging technologies & patent portfolios led to my structuring & negotiating 20 consummated license & option agreements;● Licensing revenue from 2008 to 2011 was in excess of $150 million per year for 3 1/2 years (a case study has been prepared by the Kellogg business school highlighting this NU Rx out-licensing deal).● Assisted in building & nurturing the culture of innovation to commercialization (I2C), including NU spinouts, which raised $199 million in venture/corporate investment in the academic year 2010-2011.
    View
  • Bio-Com International
    Commercial Development Executive Director - Strategic Roadmapping, Risk & Valuation Analysis
    Bio-Com International Aug 2004 - Feb 2008
    Us
    Bio-Com International is a life sciences management consultancy providing specialized I2C advisory services to enhance & sustain the competitive advantage of its clients. At the confluence of its 3 core competencies (BUSINESS, IP & BIOSCIENCE), econometric valuation tools are a key differentiator & central to the firm’s risk/reward decision-analysis & strategy-development practice areas. www.biocom.usHaving built & deployed the Bio•Biz Builder strategic commercial roadmapping & financial forecasting frameworks, including Rx economic analysis using probability-weighted capitalized & discounted cost models for pharma/biotech drug discovery & clinical development, I completed the following:► Developed strategic plans for high-impact market expansion opportunities based on forward-looking intelligence & economic analytics, including valuing 4 genomics enabled bioscience innovation to commercialization (Bio•I2C) initiatives @ $1.5 Billion.► Evaluated emerging biotechnologies, including building 12 strategic product/IP competitive roadmaps for visualizing 7 clients’ Bio•I2C landscapes. Assessed & determined value of new bioprocesses, products, licensing opps & ventures; representative client projects include:■ RNA interference (RNAi) for research & drug screening w/ an ROI of 36% IRR & 22x Cash on Cash that when realized will quadruple the public company's annual gross profit■ Active pharmaceutical ingredients (API) micronization for drug delivery/dev resulting in a $425 M risk-adj eNPV licensing opp (a PPT presentation is below)■ Automated next generation sequencing (NGS) system yielding 32% IRR & 16x CoC ROI metrics■ Proprietary formulations for addressing unmet needs in reproductive health & fertility ($2 B mkt opp)■ As CEO of startup developing proprietary OTC products, created value yielding ROI profitability for a 7 year exit of 107% IRR, 160 CoC & $990 M valuation that led to 1st B2B mfg & mktg partnership.
    View
  • Genmark Diagnostics
    Corp. Strategy & Business Development Leader @ Motorola Life Sciences Esensor Business Unit, Now:
    Genmark Diagnostics May 2002 - Aug 2004
    Carlsbad, Ca, Us
    Having successfully conducted commercial & strategy development at the genomics focused CMS business unit of MLS Life Sciences, I specifically:♦ Secured commercial IP rights for the eSensor molecular diagnostics platform & genetic content (DNA sequences & other biomarkers) for select IVD panels♦ Led strategic mDx product roadmapping & technology/market gap analysis to assess ‘build-vs.-buy’ opportunities by linking the genomics technology/IP to product functionality driven by customer’s value proposition & demand as determined by my competitive business intelligence & market research. A description of my strategic roadmapping activities is in the LI Project section. Examples of biotools roadmapping & gap analyses are provided below for other I2C projects.♦ Negotiated genomic biomarker royalty reductions up to 95% enabling multi-million-dollar cost savings by employing profitability analysis & my weighted-contribution (not rule of thumb) royalty structure;Proven 'road-tested' biotools licensing concepts also described in the Projects section.
    View
  • Applied Microarrays
    Strategic Corp. Business & New Market Development Leader | Moto Life Sci Codelink Business Unit, Now
    Applied Microarrays Sep 1999 - May 2002
    Phoenix, Arizona, Us
    Having successfully conducted strategy & commercial development for the genomics powered CodeLink business unit of MLS Life Sciences,● Identified, assessed genomic opportunities & executed biotools licenses in support of product launch of CodeLink gene expression & SNP genotyping microarray platforms with integrated system solutions;● Carried out technical, IP & business due diligence for a major diagnostics acquisition as well as other strategic business development (SBD) activities;● Created, developed & implemented biotools market development initiative for Massively-Parallel, Multi-Plexed Genomics (MPGx) commercial offering;● Received BRAVO! Leadership Award for championing non-array genomics MPGx biotools program;● Directed commercial aspects of MLS' exploratory proteomics microarray initiative;● Conducted biotech business, market & intellectual property (IP) due-diligence for MLS Ventures.
    View
  • Monogram Biosciences
    Intellectual Property Management & Licensing Director @ Aclara Biosciences, Now:
    Monogram Biosciences Feb 1997 - Sep 1999
    South San Francisco, California, Us
    Conducted genomics driven biotools intellectual property (IP) related commercial development & landscaping activities, including licensing & managing ACLARA's organic patent growth:■ Managed & built broad biotools IP portfolio (comprising of innovative microfluidics-powered genomics discovery research & high throughput screening - HTS - platforms, integrated system solutions, bioinformatics, analytics, diagnostic devices + reagents) from ~10 U.S. patents & applications to more than 130 pending & issued U.S. patents plus hundreds worldwide enabling $189 M IPO■ Co-invented microfluidic methods for drug screening/genetic analyses that resulted in 4 U.S. patents & more than a dozen pending applications/foreign equivalents■ Developed & employed preliminary freedom-to-operate & strategic market landscaping tools for visualizing & analyzing competitive technology-IP (TIP) space & new bioscience product offerings ■ Prepared & presented genomic biotools TIP marketing materials that helped lead to 3 major corporate partnerships & significant financing by way of a private placement & eventually a successful IPO.
    View

Alan K. Hauser Skills

Biotechnology Commercialization Life Sciences Technology Transfer Business Development Strategic Planning Start Ups Genomics Licensing Drug Discovery Oncology Mergers And Acquisitions Molecular Diagnostics Entrepreneurship Corporate Development Venture Capital Patents Project Management Biomarkers Business Planning Due Diligence Pharmaceutical Industry Valuation Market Development Intellectual Property Personalized Medicine Business Intelligence Companion Diagnostics Commercial Development Customer Development Product Roadmapping Strategic M&a Microarrays Microfluidics Clinical Development Contract Negotiation Strategy Marketing Biopharmaceuticals Sales Business Strategy Cross Functional Team Leadership Product Launch Management Leadership Team Building Marketing Strategy Healthcare Account Management Business Process Lifesciences Medical Diagnostics Pharmacogenomics Clinical Diagnostics Innovation Roadmap Business Modeling Biomedical Devices New Venture Creation Contract Negotiations Tech And Market Assessments M&a Experience Bioscience Genomic Tools Nucleic Acid Sample Prep

Alan K. Hauser Education Details

  • Phd Chemical & Biomolecular Engineer, Uc Berkeley; Kmi Executive Business Program, Kellogg
    Phd Chemical & Biomolecular Engineer, Uc Berkeley; Kmi Executive Business Program, Kellogg
    General Business Administration & Strategic Mktg Training
  • University Of California, Berkeley
    University Of California, Berkeley
    College Of Chemistry
  • Mit Sloan School Of Management
    Mit Sloan School Of Management
    Mit Sloan Artificial Intelligence In Pharma And Biotech Online Program
  • Harvard Business School
    Harvard Business School
    Valuation & Corporate Venture Capital
  • The University Of Chicago Booth School Of Business
    The University Of Chicago Booth School Of Business
    Private Equity & Entrepreneurial Finance
  • Northwestern University - Kellogg School Of Management
    Northwestern University - Kellogg School Of Management
    General
  • University Of Oxford
    University Of Oxford
    Shakespeare & The European Economic Community
  • North Carolina State University
    North Carolina State University
    Chemical Engineering

Frequently Asked Questions about Alan K. Hauser

What company does Alan K. Hauser work for?

Alan K. Hauser works for Health Discovery Corp.

What is Alan K. Hauser's role at the current company?

Alan K. Hauser's current role is Chief Executive Officer.

What is Alan K. Hauser's email address?

Alan K. Hauser's email address is ah****@****usa.net

What is Alan K. Hauser's direct phone number?

Alan K. Hauser's direct phone number is +165092*****

What schools did Alan K. Hauser attend?

Alan K. Hauser attended Phd Chemical & Biomolecular Engineer, Uc Berkeley; Kmi Executive Business Program, Kellogg, University Of California, Berkeley, Mit Sloan School Of Management, Harvard Business School, The University Of Chicago Booth School Of Business, Northwestern University - Kellogg School Of Management, University Of Oxford, North Carolina State University.

What are some of Alan K. Hauser's interests?

Alan K. Hauser has interest in Lean Companies, Strategic Commercial Roadmap Planning, Proteomics, Molecular And Companion Diagnostics, Genomics, Health, Sample Prep, See 7, Children, Education.

What skills is Alan K. Hauser known for?

Alan K. Hauser has skills like Biotechnology, Commercialization, Life Sciences, Technology Transfer, Business Development, Strategic Planning, Start Ups, Genomics, Licensing, Drug Discovery, Oncology, Mergers And Acquisitions.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.